Strides Pharma Science Ltd Upgraded to Buy on Strong Fundamentals and Technicals

Technical Indicators Signal Bullish Momentum

The upgrade was primarily driven by a marked improvement in Strides Pharma’s technical grade, which shifted from mildly bullish to bullish. Key technical indicators underpinning this change include a bullish stance in Bollinger Bands on both weekly and monthly charts, alongside a daily moving average that confirms upward momentum. The On-Balance Volume (OBV) indicator also supports this positive trend, showing bullish signals on weekly and monthly timeframes, suggesting strong buying interest.

While some indicators such as the MACD and KST present a mixed picture—with weekly MACD mildly bearish and KST mildly bearish on both weekly and monthly scales—the overall technical summary leans towards optimism. The Dow Theory readings are mildly bullish weekly, though mildly bearish monthly, indicating some caution but a prevailing upward trend in the near term.

Strides Pharma’s current price stands at ₹1,184.05, slightly up from the previous close of ₹1,178.40, with a day’s high of ₹1,205.00 and a low of ₹1,155.70. The stock remains close to its 52-week high of ₹1,231.45, reflecting sustained strength over the past year.

Valuation Metrics Reflect Attractive Investment Opportunity

Strides Pharma’s valuation grade has improved from very attractive to attractive, signalling a more balanced yet compelling entry point for investors. The company’s price-to-earnings (PE) ratio stands at 18.99, which is significantly lower than many of its pharmaceutical peers such as Gland Pharma (PE 42.64) and Wockhardt (PE 90.54). This valuation discount is further supported by an enterprise value to EBITDA ratio of 13.34 and an EV to capital employed ratio of 2.69, underscoring efficient capital utilisation.

The company’s PEG ratio of 0.36 indicates that earnings growth is not fully priced into the stock, offering potential upside. Return on capital employed (ROCE) at 15.54% and return on equity (ROE) at 18.64% further highlight the company’s ability to generate healthy returns relative to its capital base and shareholders’ funds.

Dividend yield remains modest at 0.42%, reflecting a focus on reinvestment and growth rather than high payout. The stock’s current price of ₹1,184.05 is trading comfortably above its 52-week low of ₹769.60, reinforcing the valuation upgrade.

Strong Financial Trends Support Positive Outlook

Financially, Strides Pharma has demonstrated consistent strength, with operating profit growing at an annual rate of 27.28%. The company has reported positive results for 12 consecutive quarters, a testament to its operational resilience. Operating cash flow for the year reached a peak of ₹702.52 crores, while the half-year ROCE hit a high of 17.96%, indicating efficient capital deployment.

Debt metrics have improved, with a debt-to-equity ratio of 0.57 times, the lowest in recent periods, suggesting a conservative capital structure. However, the debt-to-EBITDA ratio remains relatively high at 1.90 times, signalling some caution regarding debt servicing capacity.

Strides Pharma’s stock has delivered exceptional returns relative to the broader market. Over the past year, the stock has gained 34.39%, outperforming the Sensex which declined by 6.45%. Over three and five years, the stock has surged by 438.03% and 334.43% respectively, dwarfing Sensex returns of 13.48% and 29.75% over the same periods.

Quality Assessment and Risk Factors

Despite the positive momentum, certain risks remain. The company’s net sales growth over the last five years has been a modest 9.20% annually, indicating slower top-line expansion compared to operating profit growth. Return on equity averaged 9.60%, which is relatively low and suggests limited profitability per unit of shareholder funds.

Another concern is the high proportion of promoter shares pledged, currently at 38.1%, which has increased by 10.83% over the last quarter. This elevated pledge level could exert downward pressure on the stock price in volatile or falling markets, as pledged shares may be liquidated to meet margin calls.

While the company’s debt-to-EBITDA ratio of 1.90 times is on the higher side, the overall debt-to-equity ratio remains manageable. Investors should monitor the company’s ability to service debt amid evolving market conditions.

Technical and Market Performance Summary

Strides Pharma’s technical upgrade is supported by a combination of bullish signals and improving momentum. The stock’s recent weekly return of 15.70% starkly contrasts with the Sensex’s decline of 1.78%, while the one-month return of 17.58% also outpaces the Sensex’s negative 3.72%. Year-to-date, the stock has gained 31.22%, compared to the Sensex’s 11.32% loss, underscoring its resilience and investor appeal.

Over the long term, the stock’s 10-year return of 187.33% surpasses the Sensex’s 160.21%, reflecting sustained value creation. This performance, combined with improved technicals and attractive valuation, justifies the upgrade to a Buy rating with a Mojo Score of 71.0.

Conclusion: A Compelling Buy with Balanced Risks

Strides Pharma Science Ltd’s upgrade from Hold to Buy is well supported by a comprehensive improvement across technical, valuation, financial, and quality parameters. The company’s attractive valuation relative to peers, strong operating profit growth, and positive technical momentum provide a compelling investment case. However, investors should remain mindful of the risks posed by pledged promoter shares and debt servicing challenges.

Overall, Strides Pharma stands out as a promising small-cap pharmaceutical stock with consistent returns and a favourable outlook, making it a worthy addition to portfolios seeking growth in the pharmaceuticals and biotechnology sector.

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today